Abstract
The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynurenine (Kyn) that result from IDO activity. In this study, indoximod was used in combination with a checkpoint inhibitor (CPI) pembrolizumab for the treatment for advanced melanoma. Patients with advanced melanoma were enrolled in a single-arm phase II clinical trial evaluating the addition of indoximod to standard of care CPI approved for melanoma. Investigators administered their choice of CPI including pembrolizumab (P), nivolumab (N), or ipilimumab (I). Indoximod was administered continuously (1200 mg orally two times per day), with concurrent CPI dosed per US Food and Drug Administration (FDA)-approved label. Between July 2014 and July 2017, 131 patients were enrolled. (P) was used more frequently (n=114, 87%) per investigator's choice. The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P).The objective response rate (ORR) for the evaluable populat...Continue Reading
References
Aug 21, 2002·The Journal of Experimental Medicine·Guido FrumentoGiovanni Battista Ferrara
Jan 20, 2007·Cancer Research·De-Yan HouDavid H Munn
Aug 22, 2007·The Journal of Clinical Investigation·Madhav D SharmaDavid H Munn
Apr 16, 2009·Blood·Madhav D SharmaDavid H Munn
Jan 19, 2010·Investigational New Drugs·Evan M HershJeffrey S Weber
Dec 15, 2010·Immunity·Madhav D SharmaDavid H Munn
Aug 15, 2012·Immunological Reviews·Tracy L McGahaAndrew L Mellor
Jun 12, 2013·The Journal of Experimental Medicine·Rikke B HolmgaardJames P Allison
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Apr 3, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Derek A WainwrightMaciej S Lesniak
May 16, 2014·Journal for Immunotherapy of Cancer·Stefani SprangerThomas F Gajewski
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 29, 2015·Cell Reports·Rikke B HolmgaardJedd D Wolchok
Mar 24, 2016·Oncotarget·Hatem H SolimanScott J Antonia
Sep 12, 2018·Seminars in Immunopathology·Alexander J MullerGeorge C Prendergast
Jul 28, 2019·The Lancet Oncology·Caroline RobertGeorgina V Long
Dec 12, 2019·Future Oncology·Guru SonpavdeMatt D Galsky
Apr 10, 2020·Nature·Barbara MaierMiriam Merad